Mode
Text Size
Log in / Sign up

Impact of Percutaneous Coronary Intervention Complexity on Ticagrelor or Prasugrel Monotherapy EfficacyComplex heart procedures do not change risks of certain medications

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
PCI complexity does not significantly alter the safety or efficacy of potent P2Y inhibitor monotherapy versus DAPT.

This post hoc analysis of the NEO-MINDSET randomized controlled trial evaluated the impact of percutaneous coronary intervention (PCI) complexity on clinical outcomes. The study specifically compared potent P2Y inhibitor monotherapy, utilizing either ticagrelor or prasugrel, against standard dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes.

Researchers analyzed a cohort of 3,408 randomized patients, with a specific focus on 791 patients undergoing complex PCI. The primary endpoints included a composite of ischemic events—death, myocardial infarction, urgent target vessel revascularization, or stroke—and major bleeding events categorized as BARC Type 2, 3, or 5.

Results indicated that the complexity of the PCI procedure did not significantly modify the treatment effects of monotherapy compared to DAPT. Specifically, no significant interaction was observed between procedure complexity and the risk of ischemic events or major bleeding. These findings suggest that monotherapy remains a consistent alternative to DAPT regardless of the technical difficulty of the intervention.

How this fits prior evidence

How this fits prior evidence: This finding extends the evidence regarding ticagrelor monotherapy in ACS patients. It specifically addresses whether procedure complexity influences the outcomes of P2Y inhibitor monotherapy versus DAPT. This aligns with previous findings that ticagrelor and prasugrel show no statistically credible difference in 1-year MACE for ACS patients after PCI, and that ticagrelor monotherapy may reduce non-access site bleeding in STEMI patients.

When a patient faces a heart emergency, doctors must decide on the best way to keep blood flowing and prevent clots. One major concern is whether a complex procedure makes certain medications more dangerous or less effective. This study looked specifically at patients undergoing procedures for acute coronary syndromes to see if the difficulty of the surgery changed the results of their treatment.

The researchers looked at a large group of patients to compare a single potent medication against a combination of two medications. They specifically checked if the complexity of the heart procedure changed the risk of serious heart events or dangerous bleeding. The results showed that the complexity of the procedure did not change the outcomes for either group.

While these findings are helpful for understanding how these medications work in difficult cases, it is important to note that this was a post hoc analysis. This means the researchers looked back at existing data to find these specific patterns. Patients should always talk to their doctors about which treatment plan is safest for their specific heart condition.

What this means for you:
Complex heart procedures do not change the safety or effectiveness of specific blood-thinning medications.

Common questions

Does a complex heart procedure make these medications more dangerous?

The study found that the complexity of the procedure did not change the risk of bleeding for patients taking either a single potent medication or a combination of two medications. This means the risk of bleeding remained consistent regardless of how difficult the heart procedure was.

Are these medications effective for complex heart cases?

The results showed that the complexity of the procedure did not change the effectiveness of the medications in preventing major heart events. This includes outcomes like death, heart attack, or stroke, regardless of how complex the procedure was.

What specific medications were compared in this study?

The study compared a single potent medication, such as ticagrelor or prasugrel, against a combination of two medications, known as dual antiplatelet therapy. The goal was to see if the complexity of the procedure changed the outcomes for either group.

Study Details

Study typeRct
Sample sizen = 360
EvidenceLevel 2
Follow-up12.0 mo
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: Whether the anatomical complexity of percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) influences the effects of antiplatelet therapy remains unknown. AIMS: We aimed to evaluate the impact of coronary anatomical complexity on clinical outcomes in patients receiving potent P2Y inhibitor monotherapy or dual antiplatelet therapy (DAPT). METHODS: In the NEO-MINDSET trial, patients with ACS were randomised after successful PCI to 12-month ticagrelor- or prasugrel-based monotherapy or DAPT, initiated within the first 4 days of hospitalisation. The co-primary endpoints were (i) a composite of death, myocardial infarction, urgent target vessel revascularisation, or stroke; and (ii) Bleeding Academic Research Consortium (BARC) Type 2, 3, or 5 bleeding. Complex PCI was defined by one or more of the following criteria: three-vessel PCI, ≥3 treated lesions, ≥3 stents implanted, total stent length >60 mm, two-stent bifurcation, or stenting in the left main coronary artery, in a bypass graft, or in a chronic total occlusion lesion. RESULTS: Of the 3,408 randomised patients with available procedural data, 791 (23.2%) underwent complex PCI. Compared with the non-complex PCI group, patients in the complex PCI group were older (mean age 60.63±10.52 years vs 59.33±10.83 years; p=0.005) and had a higher prevalence of hypertension (67.9% vs 62.9%; p=0.010). Among patients undergoing complex PCI, 1, 2, or ≥3 complexity criteria were present in 45.5% (n=360), 22.5% (n=178), and 32.0% (n=253), respectively. PCI complexity did not significantly modify the treatment effects of monotherapy versus DAPT on the ischaemic co-primary endpoint (p-interaction=0.68). Likewise, PCI complexity did not have an effect on the comparative risk of BARC Type 2, 3, or 5 bleeding between monotherapy versus DAPT. CONCLUSIONS: In this post hoc analysis of the NEO-MINDSET trial, PCI complexity did not significantly modify the treatment effects of potent P2Y inhibitor monotherapy versus DAPT on the co-primary ischaemic or bleeding outcomes. CLINICALTRIALS: gov: NCT04360720.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.